Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > Inhaler, a mess, cost effectiveness or a strategic collab?
View:
Post by MinimumDamage on Mar 04, 2021 9:41am

Inhaler, a mess, cost effectiveness or a strategic collab?

What happened with the injectable form of nitric oxide being the key delivery method of R-107? Salzman stated that the inhaled version isn't practical or as an effective way of delivering NO. Perhaps cost effectiveness is what they're aiming for with their inhaler. However, this might also signal a strategic collaboration and are in the process of entering into similar agreements with other companies as stated in the March 3 news release.

 

Development of R-107 Nasal Spray Designed to Provide Sustained Release of Nitric Oxide in the Nasal Cavities

Comment by AngelaL on Mar 04, 2021 11:15am
The PR today explains that the inhalation route of administration is for early / mild COVID infection - this is where the virus is located in the upper airways. The injectable route is, from their earlier PR's, intended for patients with significant / serious COVID disease, where the virus has spread to the whole body and has already had a major effect on various organ systems. So each route ...more  
Comment by indaknownewfie on Mar 05, 2021 2:45pm
Agreed. The R-107 nasal apray is intended as a prophylactic. (Think condom)` and is used for what? Prevention in the nasal membrane where most of these viruses enter the body.  R-107 Nasal spray = Prevention Injectable R-107:is for those already afflicted with COVID  R-107 injection = treatment Recap: Nasal Spray = Prevention                ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities